In Brief:
In a theoretical cost-utility analysis examining post-discharge thromboprophylaxis in trauma patients, rivaroxaban was the most cost-effective agent, being both least costly and most effective. At a standard willingness-to-pay threshold of $100,000 per quality adjusted life year, all examined thromboprophylaxis agents were cost-effective when compared with no post-discharge prophylaxis.
